샘플 요청 목록

 카트 문의
시장보고서
상품코드
1571995

세계의 PEG화 단백질 시장

PEGylated Proteins
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 196 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

PEG화 단백질 시장은 2030년까지 20억 달러에 달할 전망입니다.

2023년에 11억 달러로 추정된 PEG화 단백질 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 9.1%로 성장하여 2030년에는 20억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 PEG화 단백질 소모품은 복합 연간 성장률(CAGR) 8.5%로 성장을 지속하고, 분석 기간 종료까지 13억 달러에 이를 것으로 예상됩니다. PEG화 단백질 서비스 분야의 성장은 분석 기간 동안 복합 연간 성장률(CAGR) 10.5%로 추정됩니다.

미국 시장은 2억 9,490만 달러로 추정되며 중국은 복합 연간 성장률(CAGR) 8.5%로 성장할 것으로 예측됩니다.

미국의 PEG화 단백질 시장은 2023년 2억 9,490만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 3억630만 달러 규모에 이를 것으로 예측되며 예측 기간 동안 복합 연간 성장률(CAGR)은 8.5%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 7.8%와 8.0%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 7.2%로 성장할 것으로 예측됩니다.

세계의 PEG화 단백질 시장- 주요 동향과 촉진요인 정리

기술의 진보는 어떻게 PEG화된 단백질의 발전을 촉진하는가?

단백질에 폴리에틸렌 글리콜(PEG) 사슬을 결합시키는 PEG화된 단백질은 생물학적 제제의 약동학 및 치료 효과를 개선할 수 있는 능력을 가지므로 바이오 의약품 개발에서 점점 더 중요해지고 있습니다. 단백질 공학과 PEG화 기술의 진보로 단백질을 보다 정밀하고 제어된 형태로 수식할 수 있어 치료용 단백질의 안정성 향상, 면역원성 저감, 용해성 향상으로 이어지고 있습니다. 이러한 기술 혁신을 통해 PEG화 단백질은 혈류에서 순환 시간을 늘릴 수 있어 투여 횟수를 줄이고 환자의 컴플라이언스를 향상시킬 수 있습니다. 최근의 동향에는 부위 특이적 PEG화 기술의 창출도 포함됩니다. 이것은 PEG 분자가 단백질의 제자리에 확실하게 결합하고 단백질의 생물학적 활성을 유지하는 것입니다. 또한 PEG화 화학의 진보로 PEG화효소, 펩티드, 항체의 효능이 개선되어 종양학, 면역학, 혈액학 등 다양한 치료 영역에서 보다 다용도에 응용할 수 있게 되었습니다. 이러한 혁신은 의약품 개발을 전진시킬 뿐만 아니라 생물학적 제제로 치료받는 환자의 치료 성적을 향상시키고 있습니다.

왜 PEG화 단백질은 바이오의약품으로 수요가 높은가?

PEG화 단백질 수요는 주로 단백질 기반 치료제와 관련된 많은 과제를 극복하는 능력으로 인해 바이오 의약 분야에서 빠르게 증가하고 있습니다. PEG화의 주요 이점 중 하나는 단백질의 면역원성을 감소시키고 면역계에서 인식하기 어렵고 파괴되기 어렵게 하는 능력입니다. 이 특성은 단백질 치료제의 안전성과 효능을 높이기 때문에 바이오 의약품 개발에 특히 가치가 있습니다. 또한, PEG화 단백질은 체내의 효소에 의한 분해에도 강하고 반감기가 크게 연장되므로 투여 횟수를 줄이고 환자의 어드히어런스를 향상시킬 수 있습니다. 이것은 장기 치료가 필요한 만성 질환에 특히 유용합니다. 또한, PEG화된 단백질은 표적화된 약물 전달에서도 큰 가능성을 나타내며, 표적외 효과를 최소화하면서 특정 조직 및 세포에 치료 단백질을 정확하게 전달할 수 있음 하고 있습니다. 오랫동안 작용하고 효과적이며 환자 친화적 인 생물 제제에 대한 수요가 계속 증가함에 따라 PEG 화 단백질은 차세대 치료의 중요한 구성 요소로 부상하고 있습니다.

의료 및 규제 기준의 변화는 PEG화 단백질 시장에 어떤 영향을 미치는가?

헬스케어 동향의 변화, 특히 맞춤형 의료 및 표적 치료에 대한 중점 증가는 PEG화 단백질의 채택에 큰 영향을 미칩니다. 생물학적 제형이 주요 치료제로 부상하는 동안 안전성과 효능을 높이면서 개별 환자의 요구에 맞는 치료에 대한 수요가 증가하고 있습니다. PEG화된 단백질은 사용자 정의 가능한 약동학과 부작용 프로파일의 감소로 개인화된 의료 원칙에 부합합니다. 또한, 규제 상황은 PEG화 단백질 시장 형성에 중요한 역할을 합니다. 미국 식품의약국(FDA)과 유럽의약청(EMA) 등의 규제기관은 임상적 효능과 면역원성 위험 감소를 모두 보여주는 생물제제의 승인에 주력하고 있으며, PEG화는 의약품 개발자에게 매력적인 전략입니다. 바이오시밀러, 특히 PEG화된 바이오시밀러 수요도 증가하는 경향이 있으며, 시장 확대의 새로운 기회를 제공합니다. 헬스케어 시스템이 가치 기반 의료를 점점 더 우선시하고 있는 가운데, PEG화 단백질은 안전하고 효과적이며 장시간 작용하는 생물제제의 요구에 부합하는 혁신적인 솔루션을 제공합니다.

PEG화 단백질 시장의 성장을 가속하는 요인은?

PEG화 단백질 시장의 성장은 기술의 진보, 생물 제제 수요 증가, 환자 중심의 케어 모델로의 이동 등 여러 요인에 의해 초래됩니다. 주요 원동력 중 하나는 암,자가 면역 질환, 당뇨병 등 만성 질환의 유병률 증가이며, 이들은 단백질 기반 치료에 의한 장기적인 치료가 필요합니다. PEG화된 단백질은 반감기의 연장 및 효능의 향상을 가져오고, 빈번한 투여의 필요성을 감소시키고, 환자의 어드히어런스를 향상시킵니다. 부위 특이적 PEG화 및 방출 제어 메커니즘의 기술적 진보는 시장을 뒷받침하고 있어 보다 정확한 치료 성과를 가능하게 합니다. 게다가 바이오의약품업계가 바이오시밀러의 개발에 힘을 쏟고 있다는 것도 PEG화 단백질 수요를 촉진하고 있습니다. 생물 제제 및 바이오시밀러 개발에 대한 규제 당국의 지원은 헬스케어 지출 증가와 함께 시장 성장을 더욱 강화하고 있습니다. 헬스케어 제공업체와 제약 회사가 보다 효과적이고 환자 친화적인 치료법의 개발을 목표로 하는 동안, PEG화 단백질은 생물학적 제제 치료의 진보에 중요한 역할을 하는 태세를 갖추고 있습니다.

조사 대상 기업 예(총 46건)

  • BIA Separations doo
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • IRIS Biotech GmbH
  • Jenkem Technology Co., Ltd.
  • Thermo Fisher Scientific, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

BJH 24.10.24

Global PEGylated Proteins Market to Reach US$2.0 Billion by 2030

The global market for PEGylated Proteins estimated at US$1.1 Billion in the year 2023, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2023-2030. PEGylated Protein Consumables, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the PEGylated Protein Services segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$294.9 Million While China is Forecast to Grow at 8.5% CAGR

The PEGylated Proteins market in the U.S. is estimated at US$294.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$306.3 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global PEGylated Proteins Market – Key Trends & Drivers Summarized

How Are Technological Advancements Enhancing the Development of PEGylated Proteins?

PEGylated proteins, which involve the attachment of polyethylene glycol (PEG) chains to proteins, have become increasingly important in biopharmaceutical development due to their ability to improve the pharmacokinetics and therapeutic efficacy of biologics. Advances in protein engineering and PEGylation technologies are enabling more precise and controlled modification of proteins, leading to improved stability, reduced immunogenicity, and enhanced solubility of therapeutic proteins. These technological innovations allow PEGylated proteins to have prolonged circulation times in the bloodstream, thereby reducing the frequency of dosing and improving patient compliance. Recent developments also include the creation of site-specific PEGylation techniques, which ensure that the PEG molecule attaches to a predetermined location on the protein, preserving the protein’s biological activity. Additionally, advances in PEGylation chemistry are improving the efficacy of PEGylated enzymes, peptides, and antibodies, making them more versatile and applicable across various therapeutic areas, including oncology, immunology, and hematology. These breakthroughs are not only advancing drug development but are also improving the therapeutic outcomes for patients undergoing treatment with biologics.

Why Are PEGylated Proteins in High Demand Across Biopharmaceuticals?

The demand for PEGylated proteins is rapidly increasing within the biopharmaceutical sector, primarily due to their ability to overcome many of the challenges associated with protein-based therapeutics. One of the key benefits of PEGylation is its ability to reduce the immunogenicity of proteins, making them less likely to be recognized and destroyed by the immune system. This property is particularly valuable in the development of biopharmaceuticals, as it enhances the safety and efficacy of protein therapeutics. PEGylated proteins are also more resistant to degradation by enzymes in the body, which significantly extends their half-life, allowing for reduced dosing frequencies and improved patient adherence. This is especially beneficial for chronic conditions that require long-term treatment. Furthermore, PEGylated proteins have shown considerable promise in targeted drug delivery, enabling precise delivery of therapeutic proteins to specific tissues or cells while minimizing off-target effects. As the demand for long-acting, effective, and patient-friendly biologics continues to grow, PEGylated proteins are emerging as a key component of next-generation therapies.

How Are Shifts in Healthcare and Regulatory Standards Impacting the PEGylated Proteins Market?

Shifting trends in healthcare, particularly the growing emphasis on personalized medicine and targeted therapies, are significantly influencing the adoption of PEGylated proteins. With the rise of biologics as a leading class of therapeutics, there is increasing demand for treatments that can be tailored to individual patient needs while offering enhanced safety and efficacy. PEGylated proteins, with their customizable pharmacokinetics and reduced side-effect profiles, align well with the principles of personalized medicine. Additionally, the regulatory landscape is playing a crucial role in shaping the PEGylated proteins market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are focusing on approving biologics that demonstrate both clinical efficacy and reduced immunogenic risks, making PEGylation an attractive strategy for drug developers. The demand for biosimilars, particularly PEGylated biosimilars, is also on the rise, providing new opportunities for market expansion. As healthcare systems increasingly prioritize value-based care, PEGylated proteins offer an innovative solution that aligns with the need for safe, effective, and long-acting biologics.

What Factors Are Driving Growth in the PEGylated Proteins Market?

The growth in the PEGylated proteins market is driven by several factors, including technological advancements, rising demand for biologics, and the shift toward patient-centric care models. One of the primary drivers is the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, which require long-term treatment with protein-based therapies. PEGylated proteins offer extended half-lives and improved efficacy, reducing the need for frequent dosing and improving patient adherence. Technological advancements in site-specific PEGylation and controlled-release mechanisms are also propelling the market, enabling more precise therapeutic outcomes. Additionally, the biopharmaceutical industry's growing focus on developing biosimilars is driving demand for PEGylated proteins, as they offer a cost-effective alternative to branded biologics with comparable efficacy. Regulatory support for the development of biologics and biosimilars, coupled with increasing healthcare spending, is further boosting market growth. As healthcare providers and pharmaceutical companies seek to develop more effective and patient-friendly treatments, PEGylated proteins are poised to play a critical role in advancing biologic therapies.

Select Competitors (Total 46 Featured) -

  • BIA Separations d.o.o.
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • IRIS Biotech GmbH
  • Jenkem Technology Co., Ltd.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • PEGylated Proteins - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Biopharmaceuticals Drives Growth in the PEGylated Proteins Market
    • Technological Advancements in PEGylation Processes Enhance the Stability and Efficacy of Biologic Drugs
    • Increasing Use of PEGylated Proteins in Cancer Treatment Expands Opportunities in Oncology
    • Growing Adoption of PEGylated Therapeutics in Rare Disease Treatment Strengthens Market Growth
    • Rising Focus on Prolonging Drug Half-Life Drives Demand for PEGylated Proteins in Drug Delivery Systems
    • Advancements in Site-Specific PEGylation Techniques Enhance Precision and Effectiveness of Therapeutics
    • Growing Applications of PEGylated Proteins in Immunotherapy and Vaccines Expands Market Potential
    • Increased Use of PEGylated Enzymes in Metabolic Disorders Expands Opportunities in Enzyme Replacement Therapy
    • Rising Research and Development in Biotechnology Fuels Innovation in PEGylated Protein Therapeutics
    • Technological Integration of PEGylation with Monoclonal Antibodies Enhances Targeted Drug Delivery
    • Increasing Adoption of PEGylated Proteins in Chronic Disease Management Strengthens the Case for Long-Term Therapeutics
    • Growing Use of PEGylated Liposomes in Drug Formulations Expands Market for Advanced Drug Delivery Systems
    • Rising Focus on Reducing Immunogenicity in Protein Therapeutics Drives Growth in PEGylation Technologies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World PEGylated Proteins Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for mAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for mAbs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Recombinant Factor VIII by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Protein Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Other Protein Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: USA 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: USA 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Canada 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Canada 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • JAPAN
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Japan 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Japan 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • CHINA
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: China 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: China 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • EUROPE
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe 7-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Europe 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Europe 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • FRANCE
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: France 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: France 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • GERMANY
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Germany 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Germany 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Italy 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Italy 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • UNITED KINGDOM
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: UK 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UK 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • ASIA-PACIFIC
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Rest of World 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Rest of World 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제